BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Core Points - BriaCell Therapeutics Corp. held its annual general meeting of shareholders on January 30, 2024, with 5,375,071 common shares voted, representing 33.63% of the total issued and outstanding shares [1][2]. Shareholder Resolutions - Shareholders voted overwhelmingly in favor of all proposed resolutions, including the re-appointment of MNP LLP as auditors and the election of directors [2]. - The following directors were elected with significant support: - Dr. William V. Williams: 3,487,704 votes (99.71% for) - Mr. Jamieson Bondarenko: 3,302,543 votes (94.41% for) - Mr. Marc Lustig: 3,221,128 votes (92.09% for) - Dr. Jane A. Gross: 3,491,308 votes (99.81% for) - Dr. Rebecca Taub: 3,491,351 votes (99.81% for) - Mr. Vaughn C. Embro-Pantalony: 3,489,398 votes (99.76% for) - Mr. Martin E. Schmieg: 3,486,913 votes (99.68% for) [3]. Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4].